United Neuroscience Continues Growth with Addition of Five Executives to Management Team
DUBLIN, Oct. 16, 2018 /PRNewswire/ -- United Neuroscience, Ltd., (UNS), a clinical-stage biotech company pioneering a new class of medicine to treat and prevent brain disorders, today announced five executive appointments as part of the company's continued expansion of the management team.
These appointments are Mariah DeLeon as Vice President of People, Jean-Cosme "JC" Dodart, Ph.D., as Vice President of Preclinical Development, Michael Ma, Ph.D., as Head of Research and Development Operations and Project Management, Suzanne Ostrander as Head of Clinical Operations, and Sharon Tamir as Head of External Alliances.
"The new additions bring highly accomplished executives to our scientific and operations teams," said Mei Mei Hu, Chief Executive Officer of United Neuroscience. "We are delighted to have the opportunity to benefit from all of the experience that comes from these industry veterans. These appointments also demonstrate and reinforce UNS's ability to attract seasoned individuals who will help as we advance our clinical and preclinical vaccine programs to address brain health issues."
Prior to joining UNS, Mariah DeLeon was a high-tech People Executive at Glassdoor, Innovative Interfaces, Monsoon Commerce/Alibris and Red Brick Systems. Ms. DeLeon also has experience as an Executive Coach in a variety of high-tech companies in the San Francisco Bay Area, most recently at the Public Library of Science (PLOS). She has developed and managed several global People departments and has overseen all aspects from talent acquisition to employee engagement, training and development, compensation, benefits and wellness. Ms. DeLeon earned her B.A. in organizational behavior from the University of San Francisco and her M.A. in Psychology from the California Institute of Integral Studies.
Dr. JC Dodart brings more than 20 years of experience in neuroscience drug development at both large pharmaceutical companies (Eli Lilly, Merck and Novartis) and small biotech companies (Sage Therapeutics and Wave Life Sciences). He has a strong track record of success in drug discovery and has worked in many indications, including Alzheimer's disease, neuromuscular disorders, pain and depression. Dr. Dodart earned his M.S. in cell biology and physiology from the Université Pierre and Marie Curie, France, and his Ph.D. in neuroscience from the Université Louis Pasteur, France.
Dr. Michael Ma has more than 20 years of experience in pharmaceutical, diagnostic, medical device and life science companies. Prior to joining UNS, Dr. Ma was the Director of Project Management at Ferring Pharmaceuticals, where he led global project teams in both early and late-phase development. Additionally, he held positions of increasing responsibilities at GE Healthcare, Merck, Promega and Innovir. Dr. Ma earned his B.S. and Ph.D. in bio-organic chemistry from the Université Catholique de Louvain, Belgium.
Suzanne Ostrander brings more than 20 years of experience in clinical operations with significant experience directing global clinical operations teams and conducting multinational clinical trials. Previously, she worked at Forest Laboratories (now Allergan), Regeneron, Roche, and most recently at Axovant Sciences. Ms. Ostrander earned her BA in chemistry from the University of Louisville and her MBA from Rutgers University.
Prior to joining UNS, Sharon Tamir held the position of Head of Neurodegenerative and Infectious Diseases at Karyopharm Therapeutics, where she managed a portfolio of research projects. She led multiple successful grant submission efforts to the National Institute of Health, Department of Defense and private foundations. Ms. Tamir built the neurodegenerative disease program at Karyopharm Therapeutics from hypothesis to clinical trial, resulting in a lucrative agreement for Biogen to acquire the program. Ms. Tamir received her B.A. in psychology from the Open University of Israel and her Heilpraktiker Diploma from The Trade school of Naturopathy Practitioners Saarbrucken, Germany.
About United Neuroscience
United Neuroscience Inc. (UNS) is a clinical-stage biotech company dedicated to the development of best-in-class immunotherapeutics for the brain. A global company headquartered in Dublin, Ireland, with operations in Taiwan and the United States, UNS was founded to address the social and economic burden of Alzheimer's and other neurodegenerative diseases and seeks to rapidly advance candidates into and through clinical trials with the goal of delivering breakthrough treatments to patients. For more information please visit www.unitedneuroscience.com. Follow UNS on Twitter at https://twitter.com/UNSTechBio and on LinkedIn at https://www.linkedin.com/company/unitedneuroscience.
SOURCE United Neuroscience